MaxCyte (NASDAQ:MXCT) Azioni

MaxCyte

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

MaxCyte Inc

News

Offerings

ADAG

Adagene Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Eric Joseph maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Overweight and lowers the price target from $45 to $44.

Price Target

Analyst Ratings

RCKT

JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $44

PSQH

PSQ Holdings Files For Mixed Shelf Of Up To $200M

JP Morgan analyst Cory Carpenter maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $29 to $28.

MTCH

JP Morgan Maintains Neutral on Match Group, Lowers Price Target to $28

WULF

Terawulf May Offer & Sell Shares Of Common Stock, From Time To Time, Of Up To $200M Through Or To Applicable Agent

MEGL

Magic Empire Global Files Prospectus For Offer And Sale Of Up To 15M Class A Shares

JP Morgan analyst Eric Joseph maintains Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Underweight and lowers the price target from $9 to $7.

NVAX

JP Morgan Maintains Underweight on Novavax, Lowers Price Target to $7

ACAD

ACADIA Pharmaceuticals Files For Offering Of Up To 43.6M Shares Of Common Stock By The Selling Stockholders

Biotech

Events

General

Rocket Pharmaceuticals To Present Phase 1 Clinical Trial Of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of American Society Of Gene And Cell Therapy

JP Morgan analyst Ryan Brinkman maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Overweight and raises the price target from $119 to $120.

JP Morgan Maintains Overweight on Lear, Raises Price Target to $120

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 2.11% on an annualized basis producing an average annual return of 12.39%. Currently, Danaher has a market capitalization of $135.78 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $323.32 today based on a price of $189.73 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746822613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 85.25% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 37.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 25.00% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 25.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 25.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 24.44% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 16.39% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 14.95% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 10.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 9.45% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.36% at $0.24</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 8.02% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 7.73% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 65.46% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 23.08% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 22.41% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 16.00% at $1.05</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 13.04% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 13.01% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 11.53% at $0.73</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 10.76% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 9.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 7.14% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 6.21% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 5.44% at $9.97</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 4.97% at $5.54</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed down 4.41% at $0.41</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 4.13% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 3.75% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.46% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.40% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.01% at $6.45</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

BLOZF

CBDY

CLSH

CNBX

CNGGF

CNTMF

CPHRF

CRBP

CRLBF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CWBHF

CXXIF

ELLXF

FUAPF

GNLN

GRWG

GTBIF

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

RMHB

SOLCF

TGIFF

TLRY

UGRO

XXII

Marijuana Stock Movers For May 9, 2025

Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) reported quarterly earnings of $0.33 per share. This is a 154.1 percent increase over losses of $(0.61) per share from the same period last year. The company reported $1.76 million in sales this quarter. This is a 41.96 percent decrease over sales of $3.03 million the same period last year.

Earnings

MSGM

UPDATE: Motorsport Games Q1 EPS $0.33 Up From $(0.61) YoY, Sales $1.76M Down From $3.03M YoY

Global Self Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELF#NASDAQ">SELF</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.09 by 11.11 percent. This is a 25 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $3.13 million which missed the analyst consensus estimate of $3.15 million by 0.82 percent. This is a 3.03 percent increase over sales of $3.03 million the same period last year.

Earnings Beats

Earnings Misses

SELF

CORRECTION: Global Self Storage Q1 FFO $0.10 Beats $0.09 Estimate, Sales $3.13M Miss $3.15M Estimate

CIBC analyst Hamir Patel maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Neutral and raises the price target from $32 to $33.

CIBC Maintains Neutral on Mosaic, Raises Price Target to $33

Hamilton Beach Brands Holding Company (NYSE:&nbsp;HBB) today announced that the Board of Directors has approved a 4.3% increase in the Company's regular quarterly cash dividend, raising the quarterly amount from $0.115 per share to $0.12 per share.
The dividend is payable on both the Class A and Class B Common Stock and will be paid June 13, 2025, to stockholders of record at the close of business on May 30, 2025.

Hamilton Beach Brands Hikes Quarterly Cash Dividend By 4.3% From $0.115 To $0.12 Per Share

Volcon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) reported quarterly losses of $(0.91) per share. This is a 99.97 percent increase over losses of $(2.62 thousand) per share from the same period last year. The company reported $736.05 thousand in sales this quarter. This is a 28.78 percent decrease over sales of $1.03 million the same period last year.

VLCN

Volcon Q1 EPS $(0.91), Sales $736.05K Down From $1.03M YoY

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) has outperformed the market over the past 10 years by 13.4% on an annualized basis producing an average annual return of 23.68%. Currently, Ares Management has a market capitalization of $36.04 billion. 
Buying $100 In ARES: If an investor had bought $100 of ARES stock 10 years ago, it would be worth $855.99 today based on a price of $164.95 for ARES at the time of writing.
<h3>Ares Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746821718_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Biglari Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BH#NYSE">BH</a>) reported quarterly losses of $(126.40) per share. This is a 258.87 percent decrease over earnings of $79.56 per share from the same period last year. The company reported $95.03 million in sales this quarter. This is a 6.24 percent increase over sales of $89.45 million the same period last year.

Biglari Holdings Q1 EPS $(126.40) Down From $79.56 YoY, Sales $95.03M Up From $89.45M YoY

CIBC analyst Cosmos Chiu maintains Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) with a Outperformer and raises the price target from $95 to $105.

CIBC Maintains Outperformer on Wheaton Precious Metals, Raises Price Target to $105

Press Releases

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

Management

MaxCyte Announces Retirement of Board Member Art Mandell

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

Health Care

Contracts

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance

Comments

MaxCyte

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO